secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2023-04-04T23:59:59+00:00
Accession:  0001619856-23-000055
Event type: regulatory
Sentiment:  positive
Materiality: 0.45
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Biosciences gets FDA Fast Track for CB-011 CAR-T in relapsed/refractory multiple myeloma
--------------------------------------------------------------------------------

- CB-011 is an allogeneic anti-BCMA CAR-T with immune cloaking (B2M-HLA-E transgene).
- Fast Track designation enables expedited FDA review and more frequent agency interactions.
- CaMMouflage Phase 1 trial enrolling at dose level 1; first patient dosed recently.
- CB-011 aims to be an off-the-shelf option avoiding apheresis and long manufacturing times.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000055/0001619856-23-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000055/crbu-20230404.htm
  HTML page:      https://secwatch.observer/filing/0001619856-23-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer